

Avera GI Malignancies Update

Bibliography

Jesse Guardado, MD – National Accreditation Program for Rectal Cancer (NAPRC) Overview

1. [Commission on Cancer. National Accreditation Program for Rectal Cancer](#)
2. [American College of Surgeons. Cancer Programs](#)
3. Dorrance HR, Docherty GM, O'Dwyer PJ. Effect of surgeon specialty interest on patient outcome after potentially curative colorectal cancer surgery. *Dis Colon Rectum*. 2000 Apr;43(4):492-8. doi: 10.1007/BF02237192. PMID: 10789744
4. Rickles AS, Dietz DW, Chang GJ, Wexner SD, Berho ME, Remzi FH, Greene FL, Fleshman JW, Abbas MA, Peters W, Noyes K, Monson JR, Fleming FJ; Consortium for Optimizing the Treatment of Rectal Cancer (OSTRiCh). High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action. *Ann Surg*. 2015 Dec;262(6):891-8. doi: 10.1097/SLA.0000000000001391. PMID: 26473651
5. Monson JR, Probst CP, Wexner SD, Remzi FH, Fleshman JW, Garcia-Aguilar J, Chang GJ, Dietz DW; Consortium for Optimizing the Treatment of Rectal Cancer (OSTRiCh). Failure of evidence-based cancer care in the United States: the association between rectal cancer treatment, cancer center volume, and geography. *Ann Surg*. 2014 Oct;260(4):625-31; discussion 631-2. doi: 10.1097/SLA.0000000000000928. PMID: 25203879
6. Rickles AS, Dietz DW, Chang GJ, Wexner SD, Berho ME, Remzi FH, Greene FL, Fleshman JW, Abbas MA, Peters W, Noyes K, Monson JR, Fleming FJ; Consortium for Optimizing the Treatment of Rectal Cancer (OSTRiCh). High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action. *Ann Surg*. 2015 Dec;262(6):891-8. doi: 10.1097/SLA.0000000000001391. PMID: 26473651
7. Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. *Br J Surg*. 1999 Mar;86(3):379-84. doi: 10.1046/j.1365-2168.1999.01040.x. PMID: 10201783
8. Ricciardi R, Virnig BA, Madoff RD, Rothenberger DA, Baxter NN. The status of radical proctectomy and sphincter-sparing surgery in the United States. *Dis Colon Rectum*. 2007 Aug;50(8):1119-27; discussion 1126-7. doi: 10.1007/s10350-007-0250-5. PMID: 17573548
9. Bülow S, Harling H, Iversen LH, Ladelund S; Danish Colorectal Cancer Group. Improved survival after rectal cancer in Denmark. *Colorectal Dis*. 2010 Jul;12(7 Online):e37-42. doi: 10.1111/j.1463-1318.2009.02012.x. Epub 2009 Jul 15. PMID: 19614669
10. Khani MH, Smedh K. Centralization of rectal cancer surgery improves long-term survival. *Colorectal Dis*. 2010 Sep;12(9):874-9. doi: 10.1111/j.1463-1318.2009.02098.x. PMID: 19878515
11. Ricciardi R, Roberts PL, Read TE, Baxter NN, Marcello PW, Schoetz DJ. Presence of specialty surgeons reduces the likelihood of colostomy after proctectomy for rectal cancer. *Dis Colon Rectum*. 2011 Feb;54(2):207-13. doi: 10.1007/DCR.0b013e3181fb8903. PMID: 21228670
12. Ricciardi R, Roberts PL, Read TE, Marcello PW, Schoetz DJ, Baxter NN. Variability in reconstructive procedures following rectal cancer surgery in the United States. *Dis Colon Rectum*. 2010 Jun;53(6):874-80. doi: 10.1007/DCR.0b013e3181cf6f58. PMID: 20485000

13. Swords DS, Skarda DE, Sause WT, Gawlick U, Cannon GM, Lewis MA, Scaife CL, Gygi JA, Tae Kim H. Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma. *J Gastrointest Surg.* 2019 Apr;23(4):659-669. doi: 10.1007/s11605-019-04107-1. Epub 2019 Jan 31. PMID: 30706375
14. Brady JT, Xu Z, Scarberry KB, Saad A, Fleming FJ, Remzi FH, Wexner SD, Winchester DP, Monson JRT, Lee L, Dietz DW; Consortium for Optimizing the Treatment of Rectal Cancer (OSTRiCh). Evaluating the Current Status of Rectal Cancer Care in the US: Where We Stand at the Start of the Commission on Cancer's National Accreditation Program for Rectal Cancer. *J Am Coll Surg.* 2018 May;226(5):881-890. doi: 10.1016/j.jamcollsurg.2018.01.057. Epub 2018 Mar 23. Erratum in: *J Am Coll Surg.* 2018 Oct;227(4):484-487. PMID: 29580675
15. Richardson B, Preskitt J, Lichliter W, Peschka S, Carmack S, de Prisco G, Fleshman J. The effect of multidisciplinary teams for rectal cancer on delivery of care and patient outcome: has the use of multidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome? *Am J Surg.* 2016 Jan;211(1):46-52. doi: 10.1016/j.amjsurg.2015.08.015. Epub 2015 Oct 23. PMID: 26601650
16. Lee L, Dietz DW, Fleming FJ, Remzi FH, Wexner SD, Winchester D, Monson JRT. Accreditation Readiness in US Multidisciplinary Rectal Cancer Care: A Survey of OSTRICH Member Institutions. *JAMA Surg.* 2018 Apr 1;153(4):388-390. doi: 10.1001/jamasurg.2017.4871. PMID: 29238809
17. Karagkounis G, Stocchi L, Lavery IC, Liska D, Gorgun E, Veniero J, Plesec T, Amarnath S, Khorana AA, Kalady MF. Multidisciplinary Conference and Clinical Management of Rectal Cancer. *J Am Coll Surg.* 2018 May;226(5):874-880. doi: 10.1016/j.jamcollsurg.2018.01.056. Epub 2018 Mar 23. PMID: 29580878
18. Deal SB, D'Angelica MI, Hawkins WG, Pucci M, Ujiki M, Brunt LM, Wexner S, Alseidi AA. Synoptic operative reporting for laparoscopic cholecystectomy and pancreaticoduodenectomy: A multi institutional pilot study evaluating completeness and surgeon perceptions. *Am J Surg.* 2018 Nov;216(5):935-940. doi: 10.1016/j.amjsurg.2018.06.008. Epub 2018 Jun 19. PMID: 29937324

Heidi McKean, MD – ASCO GI/ASCO 2023 Updates

1. Carlos Fernandez-Martos, Carles Pericay, Joan Maurel, Ana Virgili, Jaume Capdevila, Javier Gallego, Ruth Vera, Nuria Rodriguez-Salas, Ferran Losa, Manuel Valladares, Ana Vivancos, Juan Ayuso, Monique Maas, Fernando Martínez, Marcos Melian, and Xabier García de Albéniz. Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial. *Journal of Clinical Oncology* 2021 39:15_suppl, 3512-3512
2. Thierry Conroy, Pierre-Luc Etienne, Emmanuel Rio, Ludovic Evesque, Nathalie Mesgouez-Nebout, Veronique Vendrely, Xavier Artignan, Olivier Bouche, Alice Boileve, Matthieu Delaye, Dany Gargot, Valerie Boige, Nathalie Bonichon-Lamichhane, Christophe Louvet, Christelle De La Fouchardiere, Clotilde Morand, Veronica Pezzella, Eric Rullier, Florence Castan, and Christophe Borg. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in

- patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. *Journal of Clinical Oncology* 2023 41:17_suppl, LBA3504-LBA3504
3. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund Å, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B; Collaborative Investigators. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. *Ann Surg.* 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. Epub 2023 Jan 20. PMID: 36661037; PMCID: PMC10481913.
 4. Floris S Verheij, Dana Mohamed Rashid Omer, Hannah Williams, James T Buckley, Sabrina T Lin, Li-Xuan Qin, Hannah M Thompson, Jonathan B Yuval, Marc J Gollub, Abraham Jing-Ching Wu, Leonard B. Saltz, Julio Garcia-Aguilar, and on behalf of the OPRA Consortium. Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial. *Journal of Clinical Oncology* 2023 41:16_suppl, 3520-3520
 5. Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J Gollub, Leonard B. Saltz, Benjamin Leon Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen Fritz Kennecke, Alan P. Venook, Eileen Mary O'Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). *J Clin Oncol* 41, 2023 (suppl 17; abstr LBA2).
 6. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. *N Engl J Med.* 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5. PMID: 35660797; PMCID: PMC9492301.
 7. Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. *Lancet Oncol.* 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. PMID: 37142372.

Raed Sulaiman, MD and Erik Ehli, PhD – Molecular Diagnostic Testing Algorithm: GI Malignancies

1. NCCN Guidelines Version 2.2023. Colon Cancer
2. Dienstmann R, Salazar R, Tabernero J. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. *Am Soc Clin Oncol Educ Book.* 2018 May 23;38:231-238. doi: 10.1200/EDBK_200929. PMID: 30231342
3. Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. *J Exp Clin Cancer Res.* 2018 Mar 13;37(1):57. doi: 10.1186/s13046-018-0719-1. PMID: 29534749

4. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J Clin Oncol*. 2016 Jan 10;34(2):179-85. doi: 10.1200/JCO.2015.63.9674. Epub 2015 Oct 5. PMID: 26438111
5. Al-Shamsi HO, Alhazzani W, Wolff RA. Extended RAS testing in metastatic colorectal cancer- Refining the predictive molecular biomarkers. *J Gastrointest Oncol*. 2015 Jun;6(3):314-21. doi: 10.3978/j.issn.2078-6891.2015.016. PMID: 26029459
6. Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. *J Gastrointest Oncol*. 2016 Oct;7(5):687-704. doi: 10.21037/jgo.2016.06.12. PMID: 27747083
7. Larki P, Gharib E, Yaghoob Taleghani M, Khorshidi F, Nazemalhosseini-Mojarad E, Asadzadeh Aghdai H. Coexistence of *KRAS* and *BRAF* Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. *Cell J*. 2017 Spring;19(Suppl 1):113-117. doi: 10.22074/cellj.2017.5123. Epub 2017 May 17. PMID: 28580315
8. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol*. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10. PMID: 19001320
9. Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S. Mutations of *KRAS* and *BRAF* in primary and matched metastatic sites of colorectal cancer. *J Clin Oncol*. 2008 Sep 1;26(25):4217-9. doi: 10.1200/JCO.2008.18.7286. PMID: 18757341
10. Amatu A, Sartore-Bianchi A, Siena S. *NTRK* gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO Open*. 2016 Mar 18;1(2):e000023. doi: 10.1136/esmoopen-2015-000023. PMID: 27843590
11. Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Detection of Tumor *NTRK* Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. *J Mol Diagn*. 2019 Jul;21(4):553-571. doi: 10.1016/j.jmoldx.2019.03.008. Epub 2019 May 7. PMID: 31075511
12. Lasota J, Chłopek M, Lamoureaux J, Christiansen J, Kowalik A, Wasąg B, Felisiak-Gołębek A, Agaimy A, Biernat W, Canzonieri V, Centonze G, Chmielik E, Daum O, Dubová M, Dziuba I, Goertz S, Gózdź S, Guttmejer-Nasierowska A, Haglund C, Hałoń A, Hartmann A, Inaguma S, Iżycka-Świeszewska E, Kaczorowski M, Kita P, Kołos M, Kopczyński J, Michal M, Milione M, Okoń K, Pęksa R, Pyzlak M, Ristimäki A, Ryś J, Szostak B, Szpor J, Szumiło J, Teresiński L, Waloszczyk P, Wejman J, Wesołowski W, Miettinen M. Colonic Adenocarcinomas Harboring *NTRK* Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature. *Am J Surg Pathol*. 2020 Feb;44(2):162-173. doi: 10.1097/PAS.0000000000001377. PMID: 31567189
13. Lee SJ, Li GG, Kim ST, Hong ME, Jang J, Yoon N, Ahn SM, Murphy D, Christiansen J, Wei G, Hornby Z, Lee DW, Park JO, Park YS, Lim HY, Hong SN, Kim SH, Kang WK, Park K, Park WY, Kim KM, Lee J. *NTRK1* rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. *Oncotarget*. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. PMID: 26472021
14. Chou A, Fraser T, Ahadi M, Fuchs T, Sioson L, Clarkson A, Sheen A, Singh N, Corless CL, Gill AJ. *NTRK* gene rearrangements are highly enriched in *MLH1*/*PMS2* deficient, *BRAF* wild-type

- colorectal carcinomas-a study of 4569 cases. *Mod Pathol*. 2020 May;33(5):924-932. doi: 10.1038/s41379-019-0417-3. Epub 2019 Dec 2. PMID: 31792356
15. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol*. 2020 Apr;21(4):531-540. doi: 10.1016/S1470-2045(19)30856-3. Epub 2020 Feb 24. PMID: 32105622
 16. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchsacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: *Lancet Oncol*. 2020 Feb;21(2):e70. Erratum in: *Lancet Oncol*. 2020 Jul;21(7):e341. Erratum in: *Lancet Oncol*. 2020 Aug;21(8):e372. Erratum in: *Lancet Oncol*. 2021 Oct;22(10):e428. PMID: 31838007
 17. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumar G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. *Cancer Discov*. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23. PMID: 28336552
 18. Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2015 Dec;10(12):1670-4. doi: 10.1097/JTO.0000473485.38553.f0. PMID: 26565381
 19. Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. *Am J Surg Pathol*. 2017 Nov;41(11):1547-1551. doi: 10.1097/PAS.0000000000000911. PMID: 28719467
 20. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. *Nat Rev Genet*. 2010 Oct;11(10):685-96. doi: 10.1038/nrg2841. PMID: 20847746
 21. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Anchored multiplex PCR for targeted next-generation sequencing. *Nat Med*. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10. PMID: 25384085

22. Nathanson DR, Culliford AT 4th, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB. HER 2/neu expression and gene amplification in colon cancer. *Int J Cancer*. 2003 Jul 20;105(6):796-802. doi: 10.1002/ijc.11137. PMID: 12767065
23. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. *Mod Pathol*. 2004 Aug;17(8):895-904. doi: 10.1038/modpathol.3800137. PMID: 15143334
24. Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. *Hum Pathol*. 2010 Nov;41(11):1577-85. doi: 10.1016/j.humpath.2010.02.018. Epub 2010 Jul 24. PMID: 20656317
25. Siena. ASCO 2016. Abstr TPS774
26. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov*. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2. PMID: 22586653
27. Kuwada SK, Scaife CL, Kuang J, Li X, Wong RF, Florell SR, Coffey RJ Jr, Gray PD. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. *Int J Cancer*. 2004 Mar 20;109(2):291-301. doi: 10.1002/ijc.11686. PMID: 14750183
28. Tosi F, Sartore-Bianchi A, Lonardi S, Amatu A, Leone F, Ghezzi S, Martino C, Bencardino K, Bonazzina E, Bergamo F, Fenocchio E, Martinelli E, Troiani T, Siravegna G, Mauri G, Torri V, Marrapese G, Valtorta E, Cassingena A, Cappello G, Bonoldi E, Vanzulli A, Regge D, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Marsoni S, Siena S. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2020 Dec;19(4):256-262.e2. doi: 10.1016/j.clcc.2020.06.009. Epub 2020 Jun 27. PMID: 32919890
29. Meric-Bernstam. ASCO 2021. Abstr 3004
30. Strickler. ESMO 2019. Abstr 4795
31. Yoshino. ASCO GI 2022. Abstr 119
32. Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. *J Pathol*. 2016 Mar;238(4):562-70. doi: 10.1002/path.4679. Epub 2016 Jan 29. PMID: 26690310
33. Valtorta E, Martino C, Sartore-Bianchi A, Penault-Llorca F, Viale G, Risio M, Ruggie M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. *Mod Pathol*. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. PMID: 26449765

34. Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, Bergamo F, Fenocchio E, Martinelli E, Borelli B, Tosi F, Racca P, Valtorta E, Bonoldi E, Martino C, Vaghi C, Marrapese G, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Torri V, Marsoni S, Siena S. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. *Oncologist*. 2019 Oct;24(10):1395-1402. doi: 10.1634/theoncologist.2018-0785. Epub 2019 Apr 5. PMID: 30952821
35. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. *J Clin Oncol*. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10. Erratum in: *J Clin Oncol*. 2019 Feb 1;37(4):360. PMID: 29320312
36. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Gastric Cancer v1.2022.